Group 1 - Guanshang Technology plans to issue shares for asset acquisition and will suspend trading from December 22, 2025, with a disclosure of the transaction plan expected within 10 trading days [1][15][16] - *ST Dongyi's restructuring plan has been approved by the Beijing First Intermediate People's Court, entering the execution phase, which may improve the company's financial structure and affect its 2025 financial data [2][17] - Victory Energy's stock has hit the limit up for six consecutive trading days, with a total increase of 77.22%, indicating a significant deviation from market trends and a potential risk of rapid decline [3][18] Group 2 - Shangfeng Cement's investee, Yuexin Semiconductor, has received approval for its IPO application on the ChiNext board, with the company holding approximately 1.4957% of the equity before the public offering [4][19] - Jindalai plans to invest 30 million yuan in Zhongke Hongtai Medical Technology Co., acquiring a 10% stake in the company, which specializes in medical robotics [5][20] - Lianchuang Electronics is planning a change of control, leading to a continued suspension of its stock from December 22, 2025, for no more than three trading days [6][21] Group 3 - Health元's subsidiary has received approval for clinical trials of NS-041 tablets for treating depression, making it the only drug in China approved for both epilepsy and depression clinical studies [7][22] - Xihua Technology will be listed on the Shanghai Stock Exchange main board on December 23, 2025, with an initial public offering of 100 million shares [8][23] - *ST Mingjia has completed the capital reserve transfer to increase its share capital, resulting in an increase from 696 million shares to 1.426 billion shares, with stock resuming trading on December 22, 2025 [9][24][25]
股海导航_2025年12月22日_沪深股市公告与交易提示
Xin Lang Cai Jing·2025-12-22 00:34